WuXi Biologics
Offering End-to-End Solutions
Bioconjugate Discovery Services
Integrated ADC/Bioconjugate Discovery Services
As a trusted antibody drug conjugate CRO and CDMO, our ADC discovery services integrate all discovery functions within a unified single platform to deliver seamless workflows, expedited decision-making, fewer development bottlenecks, and lower costs and shorter timelines from initial concept through to candidate selection. Complemented by our end-to-end ADC conjugation services, we are able to compress the timeline from target identification to fully characterized ADC candidates down to 8–10 months, empowering our partners to realize faster, more efficient therapeutic innovation.
ADC lead selection timeline: ~10 months for one round
Extensive Conjugation Capabilities
The discovery services team at WuXi XDC applies multiple synthesis methods to generate bioconjugates linking payloads to biologics, which include proteins (e.g., antibodies, fusion proteins), peptides, polynucleotides, among others. We use many types of conjugation technologies including traditional cysteine conjugation and lysine conjugation, and many of the widely used site-specific conjugation methods. We support development across various carrier formats, complemented by an extensive library of linkers and payloads available to advance your R&D programs, as summarized in the table below.
Comprehensive Capabilities and Vast Project Experiences from ADC to XDC
From ADC to XDC, the boundaries of bioconjugates are continually expanding. At WuXi XDC, we have conducted a vast array of projects across bioconjugation landscape. Our capability from ADCs to XDCs:
Related Resource
Discovery Service Flyer
Scientific Poster
Antibody–Oligonucleotide Conjugates
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?
